CSMG Technologies' Live Tissue Connect Retains Top Medical Instrument Manufacturer for Its Surgical Instruments.

CORPUS CHRISTI, Texas -- CSMG Technologies, Inc., (OTC Bulletin Board: CTUM - News) a technology management company focused on commercializing tissue bonding devices, announced that their Live Tissue Connect subsidiary has signed a contract with Ventrex, Inc. www.ventrexinc.com/ for manufacturing of their electrocautery hand held surgical instruments.

Donald S. Robbins, president and CEO of CSMG, said, "We are pleased to be working with Ventrex, Inc. to develop product packaging, perform sterilization validation and to manufacture Live Tissue Connect, Inc.'s ("LTC's") hand held surgical instrument. Ventrex, Inc. is recognized throughout the medical device industry as a leader in therapeutic electrocautery instrument manufacturing and packaging. Live Tissue Connect, a subsidiary, is quickly completing its sound team of experienced medical device professionals to meet our regulatory filing, design and manufacturing needs."

LTC's Frank D. D'Amelio added, "Ventrex was selected as our disposable hand-instrument manufacturer of choice due to the breadth of their manufacturing and regulatory experience. I was impressed with their team and their level of vertical manufacturing integration. We now have all the necessary design and manufacturing companies lined-up and working on all the components required for commercialization of our first series of bipolar tissue devices."

CSMG owns the technology and exclusive world rights to the live tissue bonding device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology.

LTC expects to complete hand instruments, electrocautery generator and other electrosurgery components for the duct and vessel sealing system, meeting FDA and European CE Mark requirements, respectively. They also expect to start filing for approval of these devices with regulatory entities in early 2007.

About CSMG Technologies' Tissue Welding/Bonding Technology

The LTC tissue welding/bonding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matter in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues.

Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 7,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neurosurgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominoplasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S., Australian, Canadian and European Union patents have been issued, and additional U.S. and foreign patents are pending, all owned by LTC.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG is focused on two primary subsidiaries, Live Tissue Connect, Inc. and landfill gas processing.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to http://www.ctum.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.